Condition

Relapsing-Remitting Multiple Sclerosis

ClinicalTrials.gov condition label

Clinical trials78
Recruiting1
Common interventions25
Lead sponsors shown15

Clinical trials

60 shown
Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple SclerosisNCT07827586 · 2026-09-30
RECRUITING
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) ElevationNCT05090371 · 2022-03-02
ACTIVE_NOT_RECRUITING
Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in EgyptNCT05423769 · 2022-01-19
COMPLETED
Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled TrialNCT04971005 · 2021-08-27
TERMINATED
Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)NCT04997148 · 2021-08-11
COMPLETED
Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple SclerosisNCT04530318 · 2020-01-27
ACTIVE_NOT_RECRUITING
PET with [18F]Flumazenil As an Index of Neurodegeneration in MSNCT03825601 · 2019-05-02
COMPLETED
Behavior and Activity Monitoring in MSNCT03244696 · 2017-11-02
COMPLETED
Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and LymphocytesNCT03284970 · 2017-08-23
COMPLETED
Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With PlegridyNCT03091569 · 2017-03-10
COMPLETED
Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)NCT02428218 · 2016-05-01
WITHDRAWN
Clinical Disease Activity With Long Term Natalizumab TreatmentNCT02677077 · 2015-12-31
COMPLETED
Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple SclerosisNCT03000647 · 2015-10-01
COMPLETED
Mitochondrial Dysfunction and Disease ProgressionNCT02549703 · 2015-09-01
COMPLETED
Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl FumarateNCT02090348 · 2015-06-01
WITHDRAWN
Autologous Mesenchymal Stromal Cells for Multiple SclerosisNCT02495766 · 2015-05-11
COMPLETED
Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)NCT02323269 · 2015-05-01
TERMINATED
Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) ParticipantsNCT02342704 · 2014-11-30
TERMINATED
Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)NCT02283853 · 2014-08-28
COMPLETED
Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)NCT02159573 · 2014-07-01
COMPLETED
Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In GermanyNCT02125604 · 2014-06-01
COMPLETED
Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple SclerosisNCT02090413 · 2014-05-01
COMPLETED
A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported OutcomesNCT01930708 · 2013-10-31
COMPLETED
Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With FingolimodNCT01790269 · 2013-09-01
TERMINATED
A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple SclerosisNCT01917019 · 2013-08-01
COMPLETED
PK and PD Study of Natalizumab in Pediatric Subjects With RRMSNCT01884935 · 2013-07-01
COMPLETED
Tolerability and Quality of Life Study in Participants Who Switched to Avonex PenNCT02076841 · 2013-07-01
COMPLETED
Safety and Tolerability of Glatiramer AcetateNCT01874145 · 2013-06-01
COMPLETED
An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)NCT01838668 · 2013-03-28
COMPLETED
Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual RealityNCT01805336 · 2013-03-28
COMPLETED
Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019NCT01797965 · 2013-02-15
TERMINATED
Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis ParticipantsNCT01706107 · 2012-11-07
TERMINATED
A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple SclerosisNCT01538355 · 2012-07-30
COMPLETED
Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)NCT02142205 · 2012-05-01
COMPLETED
An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)NCT01578785 · 2012-03-01
TERMINATED
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative ParticipantsNCT01485003 · 2012-02-07
COMPLETED
Ireland Natalizumab (TYSABRI) Observational ProgramNCT01943526 · 2011-11-30
COMPLETED
An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple SclerosisNCT01462318 · 2011-11-01
COMPLETED
Effects of Electromechanical Gait Trainer in Patients With Multiple SclerosisNCT01564511 · 2011-11-01
COMPLETED
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)NCT01405820 · 2011-08-01
COMPLETED
Autologous Mesenchymal Stem Cell (MSC) Transplantation in MSNCT00813969 · 2011-03-01
COMPLETED
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® TreatmentNCT01285401 · 2011-02-01
COMPLETED
Safety Study of BIIB033 in Subjects With Multiple SclerosisNCT01244139 · 2010-10-01
COMPLETED
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple SclerosisNCT01416155 · 2010-10-01
COMPLETED
BG00012 Phase 2 Combination Study in Participants With Multiple SclerosisNCT01156311 · 2010-06-01
COMPLETED
Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple SclerosisNCT01064401 · 2010-05-01
COMPLETED
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple SclerosisNCT01051349 · 2010-03-31
COMPLETED
The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple SclerosisNCT00917839 · 2009-06-01
UNKNOWN
Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)NCT00902135 · 2009-05-01
COMPLETED
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)NCT00882999 · 2009-04-01
COMPLETED
Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMSNCT00884481 · 2009-03-23
COMPLETED
A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder FunctionNCT00818038 · 2009-03-01
COMPLETED
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)NCT00835770 · 2009-02-03
COMPLETED
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple SclerosisNCT00870740 · 2009-02-01
COMPLETED
CLARITY Extension StudyNCT00641537 · 2008-02-29
COMPLETED
Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple SclerosisNCT00390221 · 2008-02-01
COMPLETED
fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to ControlsNCT00391352 · 2008-02-01
COMPLETED
Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)NCT00559702 · 2007-10-01
COMPLETED
Tysabri Observational ProgramNCT00493298 · 2007-06-29
COMPLETED
Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple SclerosisNCT00451451 · 2007-06-01
COMPLETED

Common interventions

PlaceboDRUG13dimethyl fumarateDRUG11natalizumabDRUG5NatalizumabBIOLOGICAL4BIIB019 (Daclizumab High Yield Process)BIOLOGICAL3Glatiramer acetateDRUG3BG00012DRUG2BIIB019 (Daclizumab)BIOLOGICAL2FingolimodDRUG2Interferon beta 1aDRUG2Interferon-beta-1aDRUG2methylprednisoloneDRUG2OcrelizumabDRUG2acetylsalicylic acidDRUG1AlemtuzumabDRUG1ASA-PlaceboDRUG1Assessment of attentional functions by traditional testsOTHER1Assessment of attentional functions by virtual reality testsOTHER1Assessment of executive functions by traditional testsOTHER1Assessment of executive functions by virtual reality testOTHER1Autologous hematopoietic stem cell transplantPROCEDURE1Autologous Hematopoietic Stem Cell TransplantationDRUG1Autologous mesenchymal stem cell transplantationBIOLOGICAL1Autologous peripheral blood differentiated adult tolerogenic dendritic cells expandedOTHER1BG00002BIOLOGICAL1

Trial status mix

COMPLETED59
TERMINATED11
WITHDRAWN3
ACTIVE_NOT_RECRUITING2
UNKNOWN2
RECRUITING1

Phase mix

PHASE217
PHASE315
PHASE413
NA7
PHASE15

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.